Female Gender and Resistance to Activated Protein C (FV:Q⁵⁰⁶) as Potential Risk Factors for Thrombosis after Elective Hip Arthroplasty

Summary

Resistance to activated protein C (APC) caused by the R⁵⁰⁶Q mutation in factor V is the most common inherited risk factor for venous thrombosis. To elucidate whether APC-resistance is a risk factor for venous thrombosis after elective total hip replacement, the association between APC-resistance (presence of FV:Q⁵⁰⁶ allele) and postoperative thrombosis was investigated in patients (n = 198) randomised to received short (during hospitalisation, n = 100) or prolonged prophylaxis (three weeks after hospitalisation, n = 98) with low molecular weight heparin (LMWH). Among APC-resistant individuals receiving short prophylaxis, 7/10 developed thrombosis as compared to 2/12 receiving long prophylaxis (p <0.0179). Odds ratio for association between APC-resistance and thrombosis in the short prophylaxis group was 4.2 (CI 95% 1.02-17.5) (p <0.0465). Among those receiving prolonged, prophylaxis, there was no increased incidence of thrombosis associated with APC-resistance. Two unexpected observations were made. One was that APC-resistance was much more common in women (19/109) than in men (3/89) (p <0.001). The other was that even women without APC-resistance were much more thrombosis-prone than men. Thus, 24/48 of women with normal FV genotype and short prophylaxis developed thrombosis vs 8/42 among men, p = 0.002. The increased risk of thrombosis associated with female gender and APC-resistance was neutralised by the prolonged treatment. In conclusion, among patients receiving short prophylaxis, female gender was found to be a strong risk factor for venous thrombosis. Even though APC-resistance appeared to be a risk factor for postoperative thrombosis, the uneven distribution of APC-resistance between men and women, taken together with the increased risk of thrombosis among women, precluded valid conclusions to be drawn about the association between APC-resistance and an increased risk of thrombosis. Our results suggest that prolonged prophylaxis with LMWH after hip surgery is more important for women than for men.

• References

• 1 Bergqvist D. Postoperative thromboembolism. Frequency, etiology, prophylaxis. Berlin, Heidelberg, New York: Springer-Verlag; 1983
• 2 Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993; 80: 689-704
• 3 Clagett GP, Anderson FAJr, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108 (suppl): 312S-334S
• 4 Zimlich RH, Fulbright BM, Friedman RJ. Current status of anticoagulation therapy after total hip and total knee arthroplasty. J Am Acad Orthop Surg 1996; 04: 54-62
• 5 Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW A. Low molecular weight heparin: A critical analysis of clinical trials. Pharmacol Rev 1994; 46: 089-109
• 6 Bergqvist D, Benoni G, Bjӧrgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700
• 7 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombofilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 8 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-521
• 9 Koster T, Rosendaal FR, de RondeF, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombofilia study. Lancet 1993; 342: 1503-1506
• 10 Dahlbäck B. Inherited thrombophilia:resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614
• 11 Dahlback B, Hillarp A, Rosen S, Zoller B. Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Ann Hematol 1996; 72: 166-176
• 12 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de RondeH, van der VeldenPA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 13 Zӧller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
• 14 Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-228
• 15 Crowther MA, Hayward CPM, Hamid C, Johnston M, Gent M, Levine M, Hirsh J, Ginsberg J. Activated protein C resistance is not associated with postoperative deep vein thrombosis in patients undergoing hip or knee surgery. Blood. 1995 616. abstract.
• 16 Faunø P, Ravn HB, Lassen JF, Lund ED, Jensen J. Association between activated protein C resistance and postoperative deep vein thrombosis. Thromb Haemost 1995; 73, 1370 abstract.
• 17 Kakkar VV, Corrigan T, Spindler J, Fossard DP, Flute PT, Crellin RQ. Efficacy of low dose of heparin in prevention of deep-vein thrombosis after major surgery. Lancet 1972; 02: 101
• 18 Carter AE, Eban R. The prevention of postoperative deep venous thrombosis with dextran 70. Br J Surg 1973; 60: 681